ReviewProbiotics and antimicrobial proteins2026
Exploring the Role of Probiotics in the Prevention and Treatment of Gastrointestinal Cancer.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotics, live microorganisms with health-promoting properties, play a vital role in modulating the gut microbiota and enhancing immune responses. Their potential for regulating key signaling pathways, including NF-κB, PI3K/AKT, and Wnt/β-Catenin, suggests promise in cancer prevention as they can mitigate inflammation, strengthen intestinal barriers, and influence cytokine production, offering multiple therapeutic benefits. This review highlights the mechanisms by which probiotics may contribute to gastrointestinal cancer prevention and treatment, discussing their capacity to regulate inflammatory cytokines, enhance epithelial integrity, and balance gut microbiota. Evidence from preclinical and a growing number of clinical studies is summarized. Additionally, challenges such as strain specificity, dose optimization, and safety evaluations are analyzed alongside potential integration into conventional cancer therapies. Current data indicate that probiotics hold potential as complementary agents in oncology, possibly capable of inhibiting tumor growth, enhancing immune surveillance, and improving the efficacy of existing treatments. Future research should prioritize robust, long-term clinical trials and molecular studies to optimize their application in cancer management.
Indexed as
Identifiers
42081026What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.